Effect of sex and polymorphisms of CYP2B6 and UGT1A9 on the difference between the target-controlled infusion predicted and measured plasma propofol concentration

Ai Fujita 1,2, Kengo Hayamizu 1,3, Tatsuya Yoshihara 1,4, Masayoshi Zaitsu 5,6, Fumie Shiraishi 1, Hisatomi Arima 7, Kazumasa Matsuo 8,9, Kanako Shiokawa 8, Hidekazu Setoguchi 3,8 and Toshiyuki Sasaguri 1

Abstract

Introduction: To examine whether sex and polymorphisms of cytochrome P450 (CYP) 2B6 and UDP-glucuronosyltransferase (UGT) 1A9 affect the difference between predicted and measured plasma propofol concentration during continuous infusion by target-controlled infusion.

Results: Blood samples of 69 patients (48 men and 21 women) were obtained at 4 h after initial propofol infusion. Percentage performance error (PE) was calculated to assess the difference between measured and predicted propofol concentration. Regression coefficients (β) and 95% confidence intervals (CI) of sex and the polymorphisms of CYP2B6 and UGT1A9 for PE were, separately and mutually, estimated with linear regression. Covariates included age and body mass index in the minimal adjusted model, and additionally included clinical factors (mean blood pressure, heart rate, volume of intravenous fluid, surgical site, surgical position, and pneumoperitoneum) in the full adjusted model. PE was higher in men than in women (28.7% versus 10.5%, \( p = 0.015 \)). Female sex was inversely associated with PE: the minimal adjusted \( \beta = -8.84 \) (95% CI, \( -16.26 \) to \( -1.43 \)); however, the fully adjusted \( \beta \) with clinical factors became not significant. The average of PE did not differ between polymorphisms of CYP2B6 and UGT1A9, and \( \beta \) of CYP2B6 516G>T polymorphisms mutually adjusted with female sex was not significant. Mean blood pressure, heart rate, and volume of intravenous fluid were independently associated with PE in the full adjusted model.

Conclusions: Under 4 h anesthesia with propofol target-controlled infusion in our population, sex differences appeared to exist in the propofol concentration, which might be largely mediated by clinical factors, such as hemodynamic status.

Trial registration: UMIN-CTR UMIN000009015, Registered 1 October 2012

Keywords: Propofol, Target-controlled infusion, Polymorphism, Sex difference, Mean blood pressure, Heart rate, Volume of intravenous fluid

© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
**Background**

Propofol (2,6-diisopropyl-phenol) is commonly used in induction and maintenance of general anesthesia due to its rapid onset, relatively short emergence time, and favorable safety profile. The target-controlled infusion (TCI) system is widely used to administer propofol. Diprifusor™ is a TCI system that automatically regulates propofol dose using a pharmacokinetic model to achieve a target blood concentration [1]. Body weight is used as an input parameter for Diprifusor™. Predicted plasma propofol concentration (Cp) and measured plasma propofol concentration (Cm) were found to be correlated, in spite of the slightly greater values of Cm compared to Cp [1–4]. If Cm is higher than Cp, arousal delay may occur; if Cm is lower than Cp, it may lead to intraoperative body movement and awakening during surgery, which may result in poor prognosis for the patient.

Regarding the pharmacokinetics of propofol, sex has been reported to influence propofol metabolism and the effect of propofol, in addition to age, height, and weight [5–15]: for example, propofol metabolism in women is faster than that in men, and women awake faster than men. For clinical factors, hemodynamic state might also affect the accuracy of the TCI system [16], because the clearance of propofol depends on the hepatic blood flow [17–19].

In addition, genetic polymorphisms of the propofol metabolism enzymes have been shown to affect propofol blood concentration. The biotransformation of propofol is greatly dependent on liver metabolism [17–19], and cytochrome P450 (CYP) 2B6 and uridine diphosphate (UDP)-glucuronosyltransferase (UGT) 1A9, the main enzymes involved in propofol metabolism, are responsible for the hydroxylation and glucuronidation of propofol [20–22]. Single-nucleotide polymorphisms (SNPs) in CYP2B6 and UGT1A9 might contribute to the inter-individual variability in the rate of formation of propofol metabolites [21–23], while several studies reported no significant effect of these SNPs on propofol metabolism [7, 8, 10, 24].

Although previous studies investigated the contribution of sex and polymorphisms of propofol metabolizing enzymes on propofol blood concentration under single intravenous bolus or short-term propofol infusion [7, 8, 10–16], the influence of those factors on the accuracy of Diprifusor™ during long-term propofol infusion remains unclear.

Herein, we examined whether sex and polymorphisms of CYP2B6 and UGT1A9 affect the difference between the predicted concentration and actual plasma propofol concentration in the perioperative period with continuous propofol infusion of 4 h.

**Methods**

**Main outcome and patient selection**

The main outcome of the study was the difference between Cp and Cm around the maintenance concentration of propofol in surgery, which was evaluated using percentage performance error (PE) as follows: PE (%) = (Cm - Cp)/Cp × 100.

**Table 1** Baseline characteristics and clinical factors of the study subjects stratified by sex

| Characteristics                        | Male (n = 48) | Female (n = 21) | p value* |
|----------------------------------------|---------------|----------------|----------|
| Performance error (%)                 | 28.7 ± 28.5   | 10.5 ± 26.2    | 0.015    |
| Age (years)                           | 66.0 ± 10.7   | 66.5 ± 11.1    | 0.872    |
| BMI (kg/m²)                           | 23.3 ± 2.9    | 22.5 ± 2.4     | 0.279    |
| CYP2B6 516G > T                       |               |                |          |
| GG                                     | 35 (73)       | 13 (62)        | 0.198    |
| GT                                     | 10 (21)       | 10 (38)        |          |
| TT                                     | 31 (6)        | 0 (0)          |          |
| Volume of intravenous fluid (mL/kg)   | 31.5 ± 11.9   | 32.4 ± 13.7    | 0.773    |
| mBP (mmHg)                            | 67.1 ± 8.9    | 63.8 ± 8.5     | 0.160    |
| HR (bpm)                              | 62.8 ± 11.2   | 67.8 ± 11.6    | 0.096    |
| Surgical site (n)                     |               |                |          |
| Head and neck/upper abdomen/lower abdomen | 25/ 9/ 15   | 16/ 5/ 0       | 0.015    |
| Surgical position (n)                 |               |                |          |
| Flat position/head down position      | 37/ 11        | 21/ 0          | 0.017    |
| Pneumoperitoneum (n)                  | 3             | 2              | 0.629    |

* t-test or chi-square test

Volume of intravenous fluid means the total infusion volume from commencement of propofol infusion to the time of blood sample collection. Blood pressure and heart rate were recorded at the time of blood sample collection. BMI body mass index, mBP mean blood pressure, HR heart rate
We included patients aged ≥ 20 years, underwent anesthesia (expected anesthesia time ≥ 4 h) in spine and lateral positions by administration of propofol by TCI, and monitored with direct arterial blood pressure. We excluded those with anemia (hemoglobin < 10 g/dl), liver dysfunction (Child-Pugh B or C), renal dysfunction (eGFR < 30 ml/min/1.73m²), American Society of Anesthesiologists-physical status (ASA-PS) class III/IV, hepatic or renal surgery, and psychoneurotic disorders or psychiatric pharmacotherapy.

Of 70 eligible patients, we excluded one outlier of 39-year-old woman with a great discrepancy in Cp and Cm (PE = 267.9%) due to a possible technical error; 69 patients (48 men and 21 women) comprised the study subject. A prior analysis included the excluded patient showed the similar trend (data not shown).

**Measurement of propofol concentration and clinical parameters**

Anesthesia was induced and maintained with continuous infusion of remifentanil and propofol. A propofol TCI system (TE-371, TERUMO, Tokyo, Japan) was used to administer propofol. The infusion rates of propofol and remifentanil were adjusted by the anesthesiologists in charge according to the patients’ condition. Direct arterial blood pressure, heart rate (HR), ECG, SpO₂, central core temperature, and end tidal CO₂ were recorded throughout all operations. Bispectral index (BIS, QE-910P, Nihon Kohden, Tokyo, Japan) were applied unless it did not disturb the procedure of the surgeries.

Blood samples were collected from the radial artery at 4 h after initial propofol infusion after matching predicted blood concentration and effect-site concentration displayed on the TCI devices. When the duration of propofol infusion was < 4 h, the sample was collected before changing the target blood concentration. Mean blood pressure (mBP) and HR were recorded at the time of sample collection. Total volume of intravenous fluid was measured from initial propofol infusion to blood sample collection. Blood samples were used for gene polymorphism analysis and measurement of plasma propofol concentration. Although the time of blood pressure before blood sample collection might affect the concentration of propofol, a prior analysis using blood pressure of 10 min before blood sampling showed the same results (data not shown).

The plasma concentration of propofol was determined by a modified method of a previous report [25] by a commercial laboratory, BML, Inc. (Tokyo, Japan), using a reverse phase high-performance liquid chromatography system (Hitachi High-Technologies Corporation, Tokyo, Japan, and Shimadzu Corporation, Kyoto, Japan) with a Hypersil C18 reversed-phase column (3 μm particle size, 100 x 5.0 mm I.D.). The excitation and emission wavelength were 276 and 310 nm, respectively.

Blood samples were centrifuged (1150 g for 10 min) and stored at 4 °C. A calibration graph was created by plotting the ratios of the areas for propofol to those for thymol (internal standard) from 0.2 to 5 μg/ml. The limit of quantitation was 0.1 μg/ml.

![Fig. 1 a, b](image) Correlation of predicted plasma propofol concentration (Cp) and measured plasma propofol concentration (Cm) by sex: a men and b women. c Differences of performance error by sex.
Genotyping
Genomic DNA was extracted from peripheral blood with a DNA isolation kit (GenTLE; Takara Bio, Ohtsu, Japan). Genotyping of CYP2B6 499 C > G (rs3826711), 785 A > G (rs2279343), 1375 A > G, and 1459 C > T (rs3211371) was performed by polymerase chain reaction with restriction fragment length polymorphism method. CYP2B6 516 G > T (rs3745274), UGT1A9 i399C > T (rs2741049), and 766 G > A (rs58597806) SNPs were identified by validated TaqMan SNP Genotyping Assays (assay ID: C_78 17765_60, C_34816143_20, and C_9096281_10, respectively) (Life Technologies, Carlsbad, California, USA) using an ABI 7500 Real-Time PCR system (Life Technologies) and TaqMan® Universal Master Mix II with UNG (Life Technologies) according to the manufacturer's instruction. CYP2B6 and UGT1A9 genotypes were determined by an investigator blinded to individual information. The observed allelic frequencies conformed to Hardy-Weinberg equilibrium (data not shown).

Statistical analysis
To assess the contribution of sex and polymorphisms for PE separately, crude regression coefficients (β) and 95% confidence intervals (CI) of female sex and CYP2B6 516G > T polymorphisms were, respectively, estimated with linear regression (model 1). In addition, we minimally adjusted for baseline characteristics (age and BMI) in model 2 and fully adjusted for baseline characteristics (age and BMI) and clinical factors (mBP, HR, volume of intravenous fluid, surgical site, head down position, pneumoperitoneum) in model 3. Those covariates were adjusted as mediators for the association; other clinical factors, such as BIS scores and body temperature, were not included for covariates because those did not affect sex differences of PE in a prior analysis (Additional file 1: Table S1).

In mutual adjusted models, we included explanatory variables of female sex and CYP2B6 516G > T polymorphisms simultaneously (model 4). Additionally, we minimally adjusted for baseline characteristics (model 5) and fully adjusted for baseline characteristics and clinical factors (model 6). In the mutual adjusted models, due to the lack of female patients with CYP2B6 516TT polymorphisms, we excluded three male patients with CYP2B6 516TT polymorphisms.

Alpha was set at 0.05, and all p values were two-sided. Data were analyzed using JMP Pro 11.0.0 (SAS Institute Inc., Tokyo, Japan).

Results
The baseline characteristics and clinical factors did not differ between men and women (Table 1). Cp and Cm were statistically correlated: the correlation coefficients were, respectively, 0.73 in men (p < 0.001, Fig. 1a) and 0.50 in women (p < 0.001, Fig. 1b). The average of PE in men was significantly higher than that in women (28.7% versus 10.5%, p = 0.015, Table 1 and Fig. 1c).

The results of CYP2B6 and UGT1A9 SNPs analyses are shown in Table 2 and Additional file 2: Table S2. Although the allele frequencies for any polymorphisms did not statistically differ between men and women (Additional file 2: Table S2), the average of PE tended to differ between CYP2B6 516G > T polymorphisms (p = 0.050, Table 2).

In regression analysis, female sex was inversely associated with PE (Table 3): the minimal adjusted β = −8.84 (95% CI, −16.26 to −1.43). However, the association was substantially attenuated and became not significant on the full-adjustment with clinical factors (model 3, Table 3). Likewise, compared with CYP2B6 516GG, CYP2B6 516G > T polymorphisms was inversely associated with PE in the crude and minimally adjusted models (Table 3). However, the association was substantially attenuated and became not significant on the full-adjustment with clinical factors (model 3, Table 3). CYP2B6 516TT polymorphisms were not associated with PE.

In the mutual model, β of female sex was significant, but β of CYP2B6 516G > T polymorphisms was not significant (model 4, Table 4). The association of female sex was marginally significant on the minimal adjustment with baseline characteristics (model 5, Table 4); however, the association was substantially attenuated and became not significant in the full-adjusted model

| Polymorphisms | Performance error (%) | p value* |
|---------------|-----------------------|---------|
| **CYP2B6**    |                       |         |
| 499C > G      |                       |         |
| CC (n = 68)   | 23.4 ± 29.1           | 0.681   |
| CG (n = 1)    | 10.4                  |         |
| 516G > T      |                       |         |
| GG (n = 48)   | 26.6 ± 29.8           | 0.050   |
| GT (n = 18)   | 10.4 ± 23.5           |         |
| TT (n = 3)    | 450 ± 21.2            |         |
| 785A > G      |                       |         |
| AA (n = 36)   | 23.9 ± 29.3           | 0.534   |
| AG (n = 27)   | 19.7 ± 30.3           |         |
| GG (n = 6)    | 34.2 ± 19.9           |         |
| 1375A > G     |                       |         |
| AA (n = 68)   | 22.0 ± 27.5           | 0.681   |
| AG (n = 1)    | 100.9                 |         |
| 1459C > T     |                       |         |
| CC (n = 65)   | 22.8 ± 29.1           | 0.776   |
| CT (n = 4)    | 29.0 ± 29.9           |         |
| **UGT1A9**    |                       |         |
| i399C > T     |                       |         |
| CC (n = 10)   | 25.5 ± 22.9           |         |
| CT (n = 41)   | 21.1 ± 24.0           |         |
| TT (n = 18)   | 266 ± 41.1            |         |
| 766G > A      |                       |         |
| GG (n = 69)   | 23.2 ± 28.9           |         |

*p value of analysis of variance.
with clinical factors (model 6, Table 4). The clinical factors, mBP, HR, and volume of intravenous fluid were independently associated with PE (model 3 in Table 3 and model 6 in Table 4).

Discussion
This is the first study to investigate PE associated with sex and polymorphisms of CYP2B6 and UGT1A9, with clinical factors, after long-term propofol infusion. We found that PE in women was closer to 0 than that in men, which might indicate that the propofol TCI system is more accurate in women than in men.

A number of reports have suggested that the plasma concentration of propofol decreases more rapidly in women than in men, and that women tend to recover faster from propofol anesthesia than men [7–9, 11–15]. Loryan et al. suggested this sex difference was due to the fact that women’s livers have 1.9-fold greater CYP2B6 protein levels than men [7]. In this study, the mean PE in the perioperative period was significantly lower in women than in men, which might be caused by the sex difference of propofol pharmacokinetics.

The genetic background of propofol-metabolizing enzymes, CYP2B6 and UGT1A9, may vary propofol metabolite levels [20–22]; however, the association is controversial.

Table 3 Regression coefficients of sex and CYP2B6 516G > T polymorphisms for performance errors estimated with linear regression, adjusted for background characteristics and clinical factors

| Characteristics | Model 1 | p value  | Model 2* | p value  | Model 3† | p value  |
|-----------------|---------|----------|----------|----------|----------|----------|
| Sex (female)    | −9.13 (−16.40 to −1.85) | 0.015 | −8.84 (−16.26 to −1.43) | 0.020 | −5.43 (−12.53 to 1.68) | 0.132 |
| Age (years)     | −0.20 (−0.88 to 0.48) | 0.566 | 0.13 (−0.48 to 0.73) | 0.679 |
| BMI (kg/m²)     | 0.60 (−2.07 to 3.27) | 0.656 | 0.53 (−1.74 to 2.81) | 0.641 |
| mBP (mmHg)      | −0.80 (0.07 to 1.54) | 0.033 |
| HR (bpm)        | −0.89 (−1.43 to −0.34) | 0.002 |
| Volume of intravenous fluid (ml/kg) | −0.63 (−1.17 to −0.09) | 0.024 |
| Surgical site   |                       |       |                       |       |
| Head and neck   |                     |       |                       |       |
| Upper abdomen   |                      |       |                       |       |
| Lower abdomen   | −4.79 (−22.73 to 13.15) | 0.595 |
| Head down position | 2.98 (−11.07 to 17.04) | 0.673 |
| Pneumoperitoneum | −7.68 (−20.33 to 4.96) | 0.229 |
| $R^2$           | 0.09                 | 0.10 | 0.45                  |
| CYP2B6 polymorphisms |        |       |                      |
| 516GG           | Reference           |       | Reference           |       | Reference           |
| 516GT           | −16.93 (−31.11 to −2.74) | 0.020 | −15.68 (−30.55 to −1.11) | 0.036 | −8.72 (−21.54 to 4.11) | 0.179 |
| 516TT           | 17.65 (−4.53 to 39.83) | 0.112 | 15.68 (−7.42 to 38.77) | 0.180 | 12.12 (−7.66 to 31.90) | 0.225 |
| Age (years)     | −0.05 (−0.74 to 0.64) | 0.884 | 0.20 (−0.42 to 0.81) | 0.529 |
| BMI (kg/m²)     | 0.84 (−1.89 to 3.57) | 0.542 | 0.62 (−1.70 to 2.94) | 0.594 |
| mBP (mmHg)      | 0.98 (0.26 to 1.71) | 0.009 |
| HR (bpm)        | −0.90 (−1.45 to −0.34) | 0.002 |
| Volume of intravenous fluid (ml/kg) | −0.62 (−1.17 to −0.08) | 0.027 |
| Surgical site   |                       |       |                       |       |
| Head and neck   |                     |       |                       |       |
| Upper abdomen   |                      |       |                       |       |
| Lower abdomen   | −0.67 (−18.06 to 16.72) | 0.939 |
| Head down position | 2.37 (−11.85 to 16.58) | 0.740 |
| Pneumoperitoneum | −9.12 (−21.69 to 3.46) | 0.152 |
| $R^2$           | 0.09                 | 0.09 | 0.44                  |

*Adjusted for age and BMI (model 2)
†Additional adjustment for mBP, HR, volume of intravenous infusion, surgical site, head down position, and pneumoperitoneum (Model 3)
BMI body mass index, mBP mean blood pressure, HR heart rate
Several studies have reported the effects of SNPs in CYP2B6 and UGT1A9 on propofol metabolism [7, 20, 21, 23, 24, 26], for example, Takahashi et al. reported that D256N polymorphism in UGT1A9 lowers enzyme activity in an in vitro study, suggesting carriers of D256N might be at risk of suffering adverse effects of propofol [21]; Kansaku et al. found that SNPs CYP2B6 G516T and UGT1A9 I399C > T determined the pharmacokinetics and pharmacodynamics of propofol [23]; and Mastrogianni et al. reported a strong trend towards the association of the CYP2B6 G516T variant with high blood propofol concentrations after a single bolus dose [26]. In contrast, other studies reported no significant effects of these SNPs on propofol metabolism [7, 8, 10, 24], which partially concur with our study.

In our study, it should be noted that clinical factors of hemodynamic status (HR and mBP), which could influence the hepatic blood flow, may substantially mediate these differences of PE. A higher tendency of HR in women (Table 1, \( p = 0.096 \)) might partly explain the mediation in our study, given the fact that propofol is mostly metabolized in the liver, and the hepatic clearance of propofol depends on the hepatic blood flow [17–19]. Volume of intravenous fluid was inversely associated with PE, which could be explained by the decreased concentration of propofol due to increased plasma volume and the increased propofol metabolism rate due to increased hepatic blood flow.

This study had some limitations. First, we collected only one sample for each subject. More samples are usually collected for the external evaluation of TCI system. Second, more hemodynamic information, such as cardiac output, which can enhance liver blood flow is required. We only have the data of blood pressure and HR at the time of sample collection. Third, the target concentration of propofol was determined by the anesthesiologist in charge according to the patients’ condition because this was an observational study. Fourth, blood laboratory test was not conducted at the time of sample collection; therefore, serum albumin or hemoglobin values were not obtained. Lastly, due to the small sample size with insufficient statistical power, we could not fully assess CYP2B6 and UGT1A9 polymorphisms, in relation to sex and clinical factors. Further studies with a large number of patients are needed to clarify the influence of CYP2B6 and UGT1A9 polymorphisms on the accuracy of propofol TCI system.

**Conclusions**

The accuracy of estimated propofol concentration by Diprifusor™ TCI system appeared to differ between men and women in our population. The PE in men was higher than in women which might be mainly caused by hemodynamic status. Although this study did not show significant influence of CYP2B6 and UGT1A9 polymorphisms, further studies are expected to elucidate the effect of those polymorphisms.
The authors declare that they have no competing interests.

Competing interests

Informed consent was obtained from all patients.

2008. Patients were recruited from October 2012 to September 2013, and written with the Declaration of Helsinki, Ethical Guidelines for Clinical Research, Japan, (Registration number UMIN000009015). The study was conducted in compliance with the Declaration of Helsinki, Ethical Guidelines for Clinical Research, Japan, 2008. Patients were recruited from October 2012 to September 2013, and written informed consent was obtained from all patients.

Ethics approval and consent to participate

Ethical approval for this prospective observational study was provided by the Independent Ethics Committee of Kyushu Medical Center, Fukuoka, Japan (approval number 12-55), and registered in the UMIN Clinical Trial Registration (Registration number UMIN000009015). The study was conducted in compliance with the Declaration of Helsinki, Ethical Guidelines for Clinical Research, Japan, 2008, and Ethical Guidelines for Human Genome/Gene Analysis Research, Japan, 2008. Patients were recruited from October 2012 to September 2013, and written informed consent was obtained from all patients.

Consent for publication

Not applicable

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Received: 25 April 2018 Accepted: 3 August 2018 Published online: 13 August 2018

References

1. Glen JB. The development of "Diprifusor": a TCI system for propofol. Anaesthesia. 1998;53(Suppl 1):13–21.
2. Swinhoe CF, Peacock JE, Glen JB, Reilly CS. Evaluation of the predictive performance of a "Diprifusor" TCI system. Anaesthesia. 1998;53(Suppl 1):61–7.
3. Kazama T, Ieda K, Numata K, Kugimiyah T, Kikuchi T, Yosowaga T, Abe H, Mori K, Murakawa M, Yoshida I, Haruna M, Koh S, Matsumoto H, Yuge O, Hidaka S, Toyooka H. Assessment of use of "Diprifusor" target controlled infusion (TCI) of 1% Diprivan (CI 35,868) in [Japanese]. Anesth Resus. 1998; 34:121–39.
4. Li Y, Xu j, Yang J, Tian j, Xu j. Predictive performance of "Diprifusor" TCI system in patients during upper abdominal surgery under propofol/fentanyl anesthesia. J Zhejiang Univ Sci 2005;6:643–8.
5. Kirkpatrick T, Cockshott ID, Douglas EJ, Nimmo WS. Pharmacokinetics of propofol (diprivan) in elderly patients. Br J of Anaesth. 1988;60:146–50.
6. Schneider TW, Minto CF, Gambus PL, Andresen C, Goodale DB, Shafter SL, Youngs EJ. The influence of method of administration and covariates on the pharmacokinetics of propofol in adult volunteers. Anesthesiology. 1998; 88:1170–82.
7. Loryan L, Lindqvist M, Johansson J, Hiratsuka M, Van Der Heiden I, Van Schaik RH, Jakobsson J, Ingelman-Sundberg M. Influence of sex on propofol metabolism, a pilot study: implications for propofol anesthesia. Eur J Clin Pharmacol. 2012; 68:397–406.
8. Choong E, Loryan L, Lindqvist M, Nordling A, El Bouazzaoui S, Van Schaik RH, Johansson J, Jakobsson J, Ingelman-Sundberg M. Sex difference in formation of propofol metabolites: a replication study. Basic Clin Pharmacol Toxicol. 2013; 113:126–31.
9. Kodaka M, Suzuki T, Maeyama K, Koyama K, Miyao H. Gender differences between predicted and measured propofol CP50 for loss of consciousness. J Clin Anesth. 2006;18:486–9.
10. Kanaya A, Sato T, Fuse N, Yamaguchi H, Mano N, Yamauchi M. Impact of clinical factors and UGT1A9 and CYP2B6 genotype on inter-individual differences in propofol pharmacokinetics. J Anesth. 2018;32:236–43.
11. Gan TJ, Glass PS, Sigl J, Sebel P, Payne F, Rosow C, Embree P. Women emerge from general anesthesia with propofol/alfentanil/nitrous oxide faster than men. Anesthesiology. 1999;90:1283–7.
12. Hoymark SC, Raeder J. Why do women wake up faster than men from propofol anesthesia? Br J of Anaesth. 2005;95:627–33.
13. Wilhelm W, Buchinger H, Biedler A, Althmann S, Larsen R, Kreuer S. Influence of gender on propofol consumption and recovery times. Anaestheth. 2005; 54:567–74.
14. Haensch K, Schultz A, Krauss T, Grouven U, Schultz B. Women need more propofol than men during EEG-monitored total intravenous anesthesia. Biomed Tech (Berl). 2009;54:576–82.
15. Campell J, Fols M, Franchi F. Sex and gender aspects in anesthetics and pain medication. Handb Exp Pharmacol. 2012;214:265–78.
16. Takizawa D, Hinoaka H, Nakamura K, Yamamoto K, Horiih R. Influence of the prone position on Propofol pharmacokinetics. Anaesthes. 2004;59: 1250–1.
17. Servin F, Desmonts JM, Haberer JP, Cookshott ID, Plummer GF, Farinotti R. Pharmacokinetics and protein binding of propofol in patients with cirrhosis. Anesthesiology. 1988;69:887–91.
18. Servin F, Cookshott ID, Farinotti R, Haberer JP, Winckler C, Desmonts JM. Pharmacokinetics of propofol infusions in patients with cirrhosis. Br J of Anaesth. 1990;65:177–83.
19. Servin F, Farinotti R, Haberer JP, Desmons JM. Propofol infusion for maintenance of anesthesia in morbidly obese patients receiving nitrous oxide. A clinical and pharmacokinetic study. Anesthesiology. 1993;78:657–65.
20. Court MH, Duan SX, Hesse LM, Venkatarkrishnan K, Greenblatt DJ. Cytochrome P450 2B6 (CYP2B6) gene polymorphism of gender and sex difference in maintenance of anesthesia in morbidly obese patients receiving nitrous oxide. Anesthesiology. 2003;98:1170–82.
21. Takahashi H, Moro Y, Moriz A, Iwai M, Sato H, Takeuchi Y. Effect of D256N and Y488D on propofol glucuronidation by human urinary 5′-diphosphatase glucuronosyltransferase (UGT1A9). Basic Clin Pharmacol Toxicol. 2008;103: 131–6.
22. Moura AL, De Abreu FG, Fiegenbaum M. Impact of the cytochome P450 2B6 (CYP2B6) gene polymorphism c.516G>T (rs3745274) on propofol dose variability. Eur J Drug Metab Pharmacokinet. 2016;41:511–5.
23. Kansaku F, Kumai T, Sasaki K, Yokozuka M, Shimizu M, Tateda T, Murayama N, Kobayashi S, Yamazaki H. Individual differences in pharmacokinetics and pharmacodynamics of anesthetic agent propofol with regard to CYP2B6 and UGT1A9 genotype and patient age. Drug Metab Pharmacokinet. 2011; 26:532–7.

24. Iohom G, Ni Chonghaile M, O'Brien JK, Cunningham AJ, Fitzgerald DF, Shields DC. An investigation of potential genetic determinants of propofol requirements and recovery from anaesthesia. Eur J Anaesthesiol. 2007;24:912–9.

25. Plummer GF. Improved method for the determination of propofol in blood by high-performance liquid chromatography with fluorescence detection. J Chromatogr. 1987;421:171–6.

26. Mastrogianni O, Gbandi E, Orphanidis A, Raikos N, Goutziomitrou E, Kolibianakis EM, Tarlatzis BC, Goulas A. Association of the CYP2B6 c.516G>T polymorphism with high blood propofol concentrations in women from northern Greece. Drug Metab Pharmacokinet. 2014;29:215–8.